Anti–PD-1 Treatment May Be Associated With Improved Survival in Patients With Severe Ipilimumab-Related Toxicity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
JAMA Dermatol 2020 Jul 15;[EPub Ahead of Print], A Brunot, JJ Grob, G Jeudy, F Grange, B Guillot, N Kramkimel, L Mortier, Y Le Corre, FF Aubin, S Mansard, C Lebbé, A Blom, H Montaudie, D Giacchero, S Prey, D Legoupil, A Guyot, M Amini-Adle, F Granel-Brocard, N Meyer, M Dinulescu, J Edeline, B Campillo-Gimenez, T LesimpleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.